Labchip^® GXII Touch 蛋白分析系统提供了一种传统SDS-PAGE平板凝胶电泳的自动化替代方案，同时还提供了生物治疗药物和基因组学工作流程所需的更高通量和高质量数据。该仪器灵活支持多种试剂以进行蛋白质和核酸分析。采用易于使用的触摸屏界面，即使是临时用户也可快速准备和运行样品。Revvity提供的解决方案可确保获得一致、可重现的结果，从而满足生物治疗药物研究的需求。LabChip GxP安全软件通过兼容的软件为用户提供电子签名、电子记录保留以及访问管理。

LabChip GXII Touch HT用于还原和非还原蛋白样品表征检测，包括纯度，滴度，单抗电荷异质性，多糖筛选，片段化分析，剂型/稳定性研究等；核酸样品DNA及RNA样品的完整性分析。

At Revvity, we regard "impossibility" as inspiration and "inability" as the driving force. Revvity offers health science solutions, cutting - edge technologies and professional services, with its business covering the entire end - to - end process of scientific research exploration, development, diagnosis, and treatment. Relying on years of in - depth cultivation in fields such as translational multi - omics technology, biomarker identification, imaging, disease prediction, screening, detection and diagnosis, and informatics, Revvity is using the power of technology to break through the boundaries of human potential.

In 2023, Revvity's turnover exceeded $2.7 billion. It has more than 11,000 employees worldwide and provides diverse services for customers such as pharmaceutical and biotechnology enterprises, diagnostic laboratories, scientific research institutions and government agencies. The company is a member of the S&P 500 Index, and its customers are spread across more than 190 countries and regions around the world.